The S&P 500 ended 2024 with a 25% gain for the year. This marks the second consecutive year of gains exceeding 25% and the third such occurrence in the past four years.

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly reported this morning. I want to talk about their revenue growth number, and I'm going to put it in some context of some younger growth stocks. These are the yearly revenue growth ...

This fundamental philosophy is at the core of our investment approach across ... Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...